Journal
THERANOSTICS
Volume 11, Issue 2, Pages 861-877Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.48436
Keywords
pubescenoside A; myocardial ischemia-reperfusion injury; Kelch ECH-associating protein 1; nuclear factor erythroid 2-related factor 2; covalent modification
Categories
Funding
- National Natural Science Foundation of China [81930114, 81803765, 31700625]
- Guangdong Key Laboratory for Translational Cancer Research of Chinese Medicine [2018B030322011]
- Key-Area Research and Development Program of Guangdong Province [2020B1111100004]
- Scientific Research Team Training Project of GZUCM [2019KYTD201]
Ask authors/readers for more resources
The study demonstrated that PBA protected cardiomyocytes against OGD/R and LAD-induced MI/RI by suppressing NLRP3 inflammation activation and inducing the Nrf2 signaling pathway. PBA targeted Keap1 by selectively covalently binding to conserved cysteine residues, inhibiting Nrf2 ubiquitination and activating antioxidant enzymes.
Background and Purpose: Kelch ECH-associating protein 1 (Keap1) is a crucial chaperonin for E3 ubiquitin ligases. Modification of the key reactive cysteine residues in Keap1 affects the interaction between Keap1 and its substrate nuclear factor erythroid 2-related factor 2 (Nrf2), subsequently regulating oxidative stress and NLPR3 inflammasome activation, which are important factors for myocardial ischemia-reperfusion injury (MI/RI). Pubescenoside A (PBA), an active compound from Ilex pubescens, has antithrombotic and anti-inflammatory effects. However, the effect of PBA on MI/RI is still unknown. In the present study, we aimed to determine whether PBA can protect the heart against MI/RI and clarify the direct target and the underlying mechanism of PBA. Methods: The left anterior descending artery (LAD) ligation-induced MI/RI mice model or oxygen and glucose deprivation/reperfusion (OGD/R) were used to evaluate the cardioprotective effect of PBA. Pull-down assays, co-immunoprecipitation (Co-IP) assays, LC/MS/MS, isothermal calorimetry (ITC) experiments and covalent docking were used to identify the target of PBA. Results: PBA protected cardiomyocytes against OGD/R in vitro and LAD-induced MI/RI in vivo. PBA suppressed NLRP3 inflammation activation and induced the Nrf2 signaling pathway. Interestingly, PBA targeted Keap1 by selectively covalently binding to conserved cysteine residues, cysteine 77 (Cys77) in the BTB domain and cysteine 434 (Cys434) in the Kelch domain of Keap1, subsequently inhibiting ubiquitination of Nrf2 and activating antioxidant enzymes. Additionally, the cysteines of Keap1 has different degree of activation by PBA as follows: Cys77 > Cys434 > Cys23 > Cys38 > Cys226 > Cys273, which further elucidates the cysteine sensitivity of Keap1. Conclusions: Our results indicated that PBA might be a new Nrf2 activator that covalently binds to two critical domains of Keap1, and shows cardioprotective activities against ischemia-reperfusion injury.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available